Form 4: TERN Director Fellows Opts for Stock Options Over Cash

Terns Pharmaceuticals Director David A. Fellows elected to receive 2,828 stock options with a $34.6 exercise price in lieu of his 2026 cash retainer fee.

Summary

• David A. Fellows, a Director of Terns Pharmaceuticals, Inc. (TERN), acquired 2,828 stock options.
• The transaction date for the option grant was February 1, 2026.
• The exercise price for these stock options is $34.6 per share.
• These options were granted under the Issuer's Non-Employee Director Compensation Policy.
• Mr. Fellows elected to receive these options instead of his $75,000 cash retainer fee for the year 2026.
• The options will vest at a rate of 1/12th of the total shares on each monthly anniversary, starting from January 1, 2026, leading to full vesting by January 1, 2027.
• The expiration date for these stock options is January 31, 2036.
• Following this transaction, Mr. Fellows beneficially owns 2,828 derivative securities directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating director confidence and strong alignment with shareholder interests through the choice of equity compensation over cash.

Positives

• The director's decision to accept equity compensation over cash signals confidence in the company's future stock performance.
• This action aligns the director's financial interests more closely with those of the shareholders, promoting long-term value creation.

Negatives

• The director foregoes immediate cash compensation, exposing a portion of their remuneration to market risk and potential stock price fluctuations.

Risks

• The value of the stock options is subject to the future market price of Terns Pharmaceuticals, Inc. common stock, which can be volatile.
• If the stock price does not appreciate above the exercise price of $34.6, the options may not yield significant value.

Future Outlook

The director's decision to accept equity compensation implies a positive outlook on the future performance and stock appreciation of Terns Pharmaceuticals, Inc., aligning personal incentives with long-term shareholder value.

Management Comments

• The Reporting Person elected to receive this option in lieu of the Reporting Person's cash retainer fee of $75,000 for 2026.

Industry Context

StockSavvy.ai notes that the practice of compensating non-employee directors with equity, such as stock options, is a common and well-established corporate governance strategy across various industries, particularly in biotechnology and pharmaceuticals. This approach is designed to align the interests of directors with those of shareholders, incentivizing long-term growth and value creation.

Comparison to Industry Standards

• Equity compensation for non-employee directors is a standard practice in the biotech industry, comparable to policies at companies like Moderna, Inc. or BioNTech SE, where a significant portion of director compensation is often equity-based to foster alignment with shareholder returns.
• The vesting schedule of 1/12th monthly over a year is a typical structure for director option grants, similar to those observed in many publicly traded life sciences companies, ensuring continued engagement and commitment.

Corporate Governance

Related Party Transactions

• The grant of stock options to a director in lieu of cash compensation constitutes a related party transaction, executed under the company's established Non-Employee Director Compensation Policy.

Stakeholder Impact

• Shareholders: Potentially positive, as the director's interests are more closely aligned with long-term stock performance.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The stock options will continue to vest monthly until fully vested on January 1, 2027.
• The director may choose to exercise the vested options at any point before their expiration on January 31, 2036.

Key Dates

Recommendation

The decision by a director to take equity compensation over cash suggests confidence in the company's future performance and aligns their interests with shareholders. However, this single transaction is not a fundamental change to the company's operations or financial outlook to warrant a stronger recommendation. It is a routine compensation disclosure.

Keywords

Terns Pharmaceuticals, TERN, Form 4, insider transaction, stock option, director compensation, equity compensation, beneficial ownership